JPMorgan Chase & Co. Reiterates €100.00 Price Target for Merck KGaA (MRK)

Merck KGaA (FRA:MRK) has been given a €100.00 ($116.28) target price by JPMorgan Chase & Co. in a note issued to investors on Tuesday, February 5th. The firm presently has a “neutral” rating on the healthcare company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 8.06% from the stock’s current price.

Several other brokerages also recently issued reports on MRK. Deutsche Bank set a €93.00 ($108.14) price target on Merck KGaA and gave the stock a “neutral” rating in a report on Tuesday, October 30th. Kepler Capital Markets set a €108.00 ($125.58) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Wednesday, December 12th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Tuesday, February 5th. Morgan Stanley set a €88.00 ($102.33) price objective on Merck KGaA and gave the company a “neutral” rating in a research note on Friday, December 14th. Finally, Commerzbank set a €100.00 ($116.28) price objective on Merck KGaA and gave the company a “buy” rating in a research note on Thursday, November 8th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of €98.80 ($114.88).

Merck KGaA stock traded up €1.76 ($2.05) during trading on Tuesday, hitting €92.54 ($107.60). 721,278 shares of the company were exchanged. Merck KGaA has a 52 week low of €76.60 ($89.07) and a 52 week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Read More: Percentage Gainers

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply